GenScript Biotech Corporation, a Cayman Islands-incorporated company, announced the grant of Restricted Shares under its 2021 RSA Scheme. On June 11, 2025, the company awarded a total of 6,777,120 Restricted Shares. Among these, 6,707,292 shares were allocated to certain employees, while 69,828 shares were granted to two individual consultants engaged in technical research and strategic advisory services. This announcement highlights the company's ongoing efforts to reward and align key personnel with its growth objectives. The restricted shares were granted at no purchase price.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。